"U.S. patent application Publication 20010018191 to Mercken et al., describes monoclonal antibodies which are described as specifically able to detect only abnormally-phosphorylated tau present in brain tissue sections, in brain extracts, or in body fluids such as cerebrospinal fluid." . . . .